NEW YORK & JERUSALEM--(BUSINESS WIRE)--Ci Therapeutics (CIT), a CannRx/iCAN:Israel-Cannabis joint venture, is proud to announce positive breakthrough pre-clinical data on its ican.sleep program utilizing the patented CannTrap cannabis reactor platform developed by CannRx.
ican.sleep is the first Cannaceutical (GMP, pharmaceutical grade cannabis product) planned to be available to the tens of millions suffering from sleep disorders, a widespread ailment that affects 30% of the adult population.
CIT has identified a proprietary cannabinoid profile, CRX-102, which demonstrates a profound and consistent effect on sleep disorders. CRX-102 testing used an established, validated and predictive animal model based on a standard dose of diazepam (10 mg), a well-known and commonly used prescription drug for anxiety and sleep disorders, as a positive control. The data demonstrated that the CRX-102 product is able to generate a response rate and predictable onset of sleep similar to those of diazepam. Remarkably, CRX-102 demonstrated a statistically significantly longer duration of sleep, more than twice as long as diazepam. Moreover, there were fewer episodes of nighttime awakening and no apparent “hangover effect” upon waking.
Dr. Shimon Lecht, R&D manager of CannRx and Ci Therapeutics stated, “The effects of CRX-102 are so consistent and pronounced that one can rarely measure similar robustness of results using other investigational small molecules.”
Dr. Bill Levine, Executive Chairman of CannRx Technologies, commented, “Insomnia is a serious and widespread medical problem. Using pharmaceutical level standards of analysis and clinical testing, CannRx is developing the next generation of cannabis products that are supported by quality science, robust clinical data and a strong safety profile. Using the breakthrough CannRx technology, products that can be used to rapidly induce sleep with a prolonged “through the night” therapeutic effect will be of great benefit to this population. We are excited about the opportunity to work together with the iCAN team and launch the ican.sleep product.”
Dr. Levine will be presenting the data at the CannaTech UK conference in London on October 25-26, 2017. ican.sleep will utilize pharmaceutical grade delivery systems to provide a stable, controlled dose of a cannabis formulation, making it a breakthrough treatment in the battle for a good night's sleep.
The CannTrap platform is a proprietary technology that captures and stabilizes cannabinoids produced either by smoking, vaporizing or extraction technologies, resulting in cannabinoids that are soluble and bioavailable. The result is a rapid onset of effect with a prolonged duration of action.
Saul Kaye, co-founder of iCAN Israel-Cannabis, said of the new findings, "As an insomniac myself, I am proud to be involved in bringing next generation cannabis products to the market. ican.sleep has been developed & formulated to be used with our medical grade personal portable nebulizer. ican.sleep will provide, for the first time, a non-combusting, dosable, inhalation solution for people looking for advanced cannabinoid formulations. These strong results validate our collaboration with CannRx. We are excited to plan the launch of ican.sleep in mid-2018.”
About CannRx Technology
Initially formed as a subsidiary of Izun Pharmaceuticals Corporation ("Izun"), CannRx has a unique technological advantage due to its relationship with Izun, a company with 16 years of success in the specialty pharma area of botanical medicine. Izun has several pharmaceutical products approved in Europe and the US. CannRx's laboratory in Israel is the Israeli Ministry of Health's leading testing laboratory for cannabis and the only laboratory with ISO 17025 certification.
CannRx has developed highly accurate quantitative and qualitative analytical chemical assays, as well as disease-specific bioassays, to determine the activity of specific cannabinoids in the cannabis plant. CannRx has also designed unique and proprietary delivery systems for medical cannabis that increase bioavailability and provide precise dosing of cannabis-based medicines. Its technology provides the benefit of lower doses with increased and prolonged effects and a reduction in side effects.
About iCAN:Israel-Cannabis
iCAN is a globally recognized Israeli company focused on the medical cannabis industry. iCAN develops novel cannabis formulations and devices and creates globally recognized brands utilizing cutting-edge extraction and formulation technology, as well as FDA approved devices, to deliver a unique product, clearly defined by clinical evidence. iCAN operates across all verticals of the value chain, offering services from consulting and business development, mentoring, investment strategy, network and media, compliance and regulation, CRO, commercialization, formulation and international distribution. Our team of experienced professionals adds to the industry know-how necessary for navigating and maximizing this rapidly developing global industry. Our portfolio of companies synergistically allows iCAN to add value to each unit and to drive global sales and development.
Disclosure Notice:
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.
Investors are cautioned not to place reliance on these forward looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
